Traws Pharma (TRAW) Stock Forecast & Price Target

Traws Pharma is viewed positively because the 1Q26 update materially de-risked its lead program by securing a funding path through 1Q27, with the April PIPE providing $10.0M upfront and up to $60.0M in total potential gross proceeds to support the planned TXM human influenza challenge trial. Its core thesis remains compelling as tivoxavir marboxil advances from an ongoing Phase 1 bridging study in Australia, under an open IND and with MHRA approval, toward a single-dose challenge study at hVIVO in the U.K., while the company’s 28-day coverage goal supports a once-monthly prophylaxis angle. That broader framing expands the opportunity beyond H5N1 preparedness and Strategic National Stockpile optionality into seasonal influenza prevention, and combined with ratutrelvir’s potential as a ritonavir-free COVID antiviral, it creates meaningful upside relative to the current market cap.

Traws Pharma is facing a deteriorating fundamental outlook because its planned tivoxavir marboxil Phase 2a human influenza challenge study was deferred after a negative MHRA review, while the FDA had already placed the U.S. IND on clinical hold over toxicology concerns. That removes the company’s clearest near-term value driver and suggests regulator-level issues that may require additional work or a backup-candidate strategy, rather than a quick path to validation. Although it reported $3.1M in cash on 3/31/2026 and secured April PIPE financing with up to $60M of potential proceeds, the company still has a 1Q27 runway and faces a weaker COVID market, where Paxlovid sales fell to $186M in 1Q26 from $1.2B in 3Q25.